Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR0302 in Moderate to Severe Active Crohn's Disease (Phase II)
CTR20182464Phase 2Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ivarmacitinib in Crohn's disease, sponsored by Hengrui Therapeutics. Started Jan 2019; status: completed.
02
Drugs
ivarmacitinib
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on CTR20182464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20182464.